<scp>GIDEON</scp> (Global Investigation of therapeutic <scp>DE</scp> cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in > 3000 patients are ongoing.